49 programming-"St"-"FEMTO-ST"-"University-of-St"-"UCL"-"St" positions at Nature Careers in Canada
Sort by
Refine Your Search
-
innovative Population Health Data Science research programs. We will consider applicants spanning all areas of Population Health Data Science, including complex disease epidemiology, infectious disease
-
program at Queen’s, which already includes 38 full-time Faculty and over 200 graduate students and postdocs. The preferred start date for the position is July 1, 2026. Tier 2 Canada Research Chair Canada
-
Nature Careers | Halifax Mid Harbour Nova Scotia Provincial Government, Nova Scotia | Canada | 2 months ago
. Applicants with a PhD or equivalent with an exceptional emerging research program in biomedical data science with application in precision medicine will be considered for this CRC position. The ideal candidate
-
program. Position Summary The MacDonald Lab (www.bcell.org) at the Alberta Diabetes Institute would like to hear from postdoctoral candidates with a keen interest in advancing understanding of insulin and
-
. The appointee to the LEEF Chair will be nominated for the Canada Excellence Research Chair (CERC). The CERC program, Canada’s highest research chair appointment, is designed to attract and support world-renowned
-
Nature Careers | Victoria Central British Columbia Provincial Government, British Columbia | Canada | 3 months ago
chemistry is required and Post-doctoral experience is strongly preferred. In accordance with the University’s Equity Plan and pursuant to section 42 of the BC Human Rights Code, the selection will be limited
-
Program research grant, this project brings together complementary expertise of the Zhulyn (Canada), Lagha (France), vanOudenaarden (Netherlands) and Kelleher (US) labs for a team-driven, multidisciplinary
-
to provide expert scientific guidance and hands-on support for our R&D team. As we rapidly advance our novel cell therapy program for oncology, your deep expertise in immunology, T-cell biology, and cancer
-
in preclinical testing. The core technology has FDA approval for Phase I trials, but needs optimization on the I.P., scale manufacture and antigen production areas. Our plan is to leverage emerging